imetelstat provides durable transfusion independence in lower risk mds group
Published 5 years ago • 748 plays • Length 9:38Download video MP4
Download video MP3
Similar videos
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
3:12
prolonged & continuous transfusion independence after imetelstat treatment in the imerge trial
-
2:19
imetelstat for transfusion-dependent r/r mds
-
3:50
imetelstat efficacy is independent of molecular subtypes in r/r lr-mds
-
2:05
does imetelstat increase the need for platelet transfusions & growth factors in pts with lr-mds?
-
9:36
imetelstat provides durable transfusion independence in heavily transfused non-del(5q) lr-mds r/...
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
3:56
which patients with mf could benefit the most from telomerase inhibitors?
-
3:54
blood cancer treatment could be transformed by discovery
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
1:24
imetelstat in high-risk triple-negative myelofibrosis
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
2:40
imerge results: efficacy and disease-modifying activity of imetelstat in lr-mds after esa failure
-
3:47
current and emerging treatment options for lr-mds-associated anemia following esa failure
-
2:25
master final analysis: quadruplet induction therapy, asct & mrd-adapted treatment cessation in ndmm
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
1:44
an update on imetelstat in r/r myelofibrosis